ABHI Annual Report 2011

Innovative, safe & effective medical technologiesAssociation of British Healthcare IndustriesAnnual Report 2011/12

Association of British Healthcare Industries

Exeter Hip JointStryker

ABHI Annual Report 2011/12

ABHI: Advancing Access to Medical TechnologyVision: To lead the advocacy of the UK medical technology industryMission: To champion the benefits and use of safe and effective medical technologies in delivering high quality patient outcomes

Contents01 Achievements 201102 Strategic Review03 Priorities 201204 Chairman and Chief Executive Round Table06 UK Market08 International10 Regulation12 Ethics and Compliance13 ABHI Groups Structure14 ABHI Board of Directors15 ABHI Staff and Membership List

Association of British Healthcare Industries 1

“If the NHS is to meet the combined challenges of an ageing population, tighter economic climate, chronic disease and health inequalities it must innovate. That will mean working more closely with our key stakeholders, including organisations like the ABHI. We need to develop relationships based on mutual interest, trust and partnership to deliver the type of transformational change that will deliver healthcare of the highest quality and value to patients and the NHS, and drive economic growth in UK plc.”

Miles AylingDirector of Innovation and Service Improvement Commissioning and System Management Directorate

UK Market• Challenged and halted NHS Supply Chain’s

“Direct From Manufacturer – Choice for Health” initiative.

• Stopped NHS Supply Chain’s “additional management fees” practice in tenders.

• Completed legal review of procurement intermediaries’ “activity based income” business model. Response to NHS underway.

International• Re-aligned ABHI’s International strategy, future focus

and re-established ABHI’s International Policy Group.

• Delivered international exhibition programme, and provided market access information and advice to 400+ companies.

Regulatory and Standards• Successfully lobbied for the creation of a clearly

defined Devices Division in MHRA.

• Aligned, MHRA and Government with industry position on Medical Device Directives Revision.

• Alignment of EU and UK policies on Unique Device Identification at Ministerial and Department level.

Ethics and Compliance• Concordat signed with Medilink UK underpinned by

agreement to sign-up its members to the ABHI Code of Business Practice (CoBP).

• Publication and promotion of Advertising Annex.

Achievements 2011

2 Association of British Healthcare IndustriesAssociation of British Healthcare Industries2

NexGen® LPS-Flex Mobile KneeZimmer

ABHI Strategic Review2011 has been a year of significant change in the NHS and ABHI has worked hard to keep pace with the changes and evolve the Association accordingly.

On January 1, ABHI constituted its Board of Directors as a direct result of changes made to the the Association’s governance arrangements in 2010. Initially under the Chairmanship of Gary Stapleton (then Managing Director of 3M Healthcare UK) and latterly Johnny Lundgren (Vice President Northwest Europe of Becton Dickinson) the ABHI Board has provided leadership and guidance to ensure the Association meets its stakeholders’ needs.

The Board has played a critical role in defining the strategic direction for ABHI and its priorities for 2012.

The value ABHI provides to its stakeholders was identified in the strategic review undertaken in 2010 as follows:

• the ability to provide strategic leadership to the medical technology industry, and

• to influence and shape the health system policy environment.

In translating this value into strategies, the review process identified four strategy pillars critical to ensuring that members operate in a favourable business environment. The Board agreed that the overriding strategy is to develop, influence and shape policy as it relates to each of these strategic pillars, reimbursement, with both PbR and Part IX likely to be impacted.

“The Government is determined that the UK should be a world-leading place for life sciences investment, innovation and adoption. That determination underpins the Strategy for UK Life Sciences and the report Innovation Health and Wealth which we published at the end of 2011. Collaboration across the public and private sectors – and not least between industry associations and government – is central to their message and to their implementation. I value the important and constructive role ABHI plays in that continuing dialogue.”

Earl Howe Minister of State for Innovation

Strategic Review


ABHI Priorities 2012

UK Market:• Create industry position on procurement and gain

NHS agreement.

• Establish clear and structured relationship with NHS Commissioning Board.

• Adopt industry leadership role on implementation of IHAW key recommendations.

International• Develop industry position on trade support

mechanisms and influence Government.

• Minimise barriers to trade with China, Brazil and India.

Regulation & Standards• Ensure industry positions on MDD Revision reflected

in UK input to “Formal Proposal”.

• Establish clear and structured relationship with MHRA Devices Division.

Ethics & Compliance:• Establish ABHI CoBP as standard for all NHS

interactions with suppliers.

• Develop member employee accreditation system for interaction with NHS.

Priorities 2012

Trabecular Metal Hip Joint Zimmer

Working to this direction, ABHI has begun to align resource, set objectives and report achievements against each of the four pillars.

ABHI’s key priorities for 2012 are indicated below:

Association of British Healthcare IndustriesAssociation of British Healthcare Industries4

Chairman and CE Round Table

What did yousee as the major developments of 2011?

#1

How will these developments affect industry in 2012?

#2

“The decision by NHS Supply Chain to cease their Direct from Manufacturer programme, following intensive lobbying from ABHI, was a major development for industry. The publication of Innovation Health and Wealth heralded a major step forward in the Government’s attitude towards the uptake of innovation in the NHS. It has been long acknowledged that the NHS is a slow and late adopter of innovation, this report heralded a new way of looking at this problem. We will be working with Government to ensure the recommendations are implemented in 2012. The national press was dominated by talk of the Health and Social Care Bill throughout 2011. ABHI were able to have a significant input into each stage of this process, culminating with the drafting of a number of amendments at second reading in the Lords.”

Peter Ellingworth

“The approach to both these documents from the government side feels different from the past. There is a real commitment to implementation and genuine personal capital invested by ministers. We all need to understand the implications for us and consider how best to maximise what is a once in a decade opportunity. The association is well placed to drive many of the outputs in a positive direction and we will be counting on the suppport, insight and evidence base of our members to do so.”

Johnny Lundgren

“It is difficult to look past the health and social care bill, as it consumed so much time and energy for both ourselves and others. But when the dust settles and whatever will happen with the bill has happened, I think we will look at the autumn package – the Chief Executive’s Review, Innovation Health and Wealth and the lifesciences strategy as the things that defined the year. We were heavily involved in both and I think the positive influence of our industry is reflected in many of the recommendations.”

Johnny Lundgren

“The recommendations contained in Innovation Health and Wealth will have a major impact on industry in 2012. This report acknowledges the need for innovation to lead the way in shifting healthcare delivery and working more efficiently, not to ‘salami slicing’ services to make short term savings at the expense of patient care. The reforms set out in the Health Bill continue to take shape, with structures such as SHAs and PCTs soon to disappear, the medical device industry will have to respond quickly to these changes and adapt to the new landscape if we are to help shape the future of the NHS, not get left behind.”

Peter Ellingworth

Peter EllingworthChief Executive

Johnny LundgrenChairman


How can ABHI continue to support members effectively as the pace of change accelerates?

#4

What do you see as the key challenges facing the medical device industry in 2012?

#3

“The key challenge for industry will be continued growth at a time of reduced NHS budgets and low economic growth. The Publication of ‘Strength and Opportunity: the Medical Technology Database’ showed that industry was able to grow throughout 2011. As healthcare providers continue to scrutinise their spending more closely the challenges for industry will be to provide the evidence that demonstrates the value of our technologies and the treatments they support. This year will also see the Revision of the Medical Device Directives enter the European Parliament, with a Proposal expected from the European Commission by the summer. It is crucial that the Regulatory Regime in Europe continues to deliver patient safety whilst delivering innovative treatments to patients at the appropriate time. The challenge for 2012 will be to continue our constructive engagement with policy makers to ensure the regulatory regime remains fit for purpose.”

Peter Ellingworth“There are two familiar themes that we must never grow weary of talking about. The fine words and noble intentions of the centre can and are undone at a stroke by operational behaviour in the wider NHS. If the levers and incentives imposed on those charged with the day to day procurement of goods and services continue to focus on the immediate term, then the opportunity to unlock the power of technology to deliver real productivity gains for the NHS will once again be lost. We have yet to do a good enough job in articulating the value proposition of our industry. It is a challenge that will not go away. We had some success in highlighting the shortcomings of the NHS’ own direct from manufacturers scheme, but we will need to be able to respond quickly and appropriately to the procurement review when it is published in March. The other area is regulation. It seems that not a week has gone by in 2012 so far when we have not been faced with a maelstrom of criticism about the way devices are regulated. Many, seemingly credible commentators are convinced that our approval system is not fit for purpose. Through the revision of the medical device directives and beyond, we have an obligation to explain to just about everyone we meet that the way devices are regulated both offers timely access to the best available technology and protects the patients we serve.”

Johnny Lundgren

“The Association has never been busier nor has it ever been in a better position to influence improvements in the delivery of healthcare in our country. But to continue to do this successfully, we need the energy, enthusiasm and commitment of all our members. In 2012 we should use every meeting of every working group to re-energise and, where necessary, re-focus our efforts for the benefits of workers and patients throughout the healthcare system.”

Johnny Lundgren

“2011 was the first year in ABHI’s history that we were led by an elected Board of Directors. The Board hit the ground running early in 2011 and set clear goals for the association last year. I was pleased that we are able to achieve these goals, and looking forward to working towards achieving the strategic goals we have agreed for 2012. Much of this work will require us to continue to keep pace with the changes in the healthcare environment and ensure that we represent industry appropriately. With the Board now a year old and continuing to set clear goals for the association I am confident we will be able to continue to support the med device industry effectively.”

Peter Ellingworth


“We are actively involved with ABHI as this gives us a collective and consistent voice with policy-makers and Government/NHS organisations. The participation of many of our staff in ABHI policy groups and working groups is beneficial for our development as they have the opportunity to work with professional and experienced people from a diverse range of companies.”

Mark McIntyreUK Group Director of Public Affairs and Health EconomicsBoston Scientific

UK Market

For ABHI, and probably for most of our members, it is difficult to believe that changes in the business environment are ever for the better. Over the last five or six years, the landscape of commercial dealings with the NHS has become more and more complicated. Added to this is the downward pressure on expenditure which has gained momentum over the last few years.

Against this background, ABHI’s Board played an important role in steering activity in 2011. This was pivotal and the Association made progress in a number of key areas. First, the Board set some key objectives for commercial policy in the market, particularly regarding the own brand activity initiated by NHS Supply Chain but also relating to the role of procurement intermediaries in the NHS. Second, the Board helped the Association to develop relationships with NHS leaders. The resulting commitments look likely to make a positive difference in 2012 and beyond. The third key emphasis for ABHI in 2011 was on understanding and a influencing the shape of the Health & Social Care Bill introduced in January 2011 following the White Paper, ‘Liberating the NHS’, published in summer 2010. We briefed MPs on a range of issues during the Commons committee stages and a number of Lords during the more recent committee stage in the Upper Chamber. This contributed to a thought-provoking debate on 13 December 2011 when the drawbacks of the existing arrangements for tariff and innovation were explicitly recognised by the Minister, Earl Howe.

ProcurementThe Key Achievements section in this annual report summarises some of the progress made regarding the NHS Supply Chain’s “Direct from Manufacturer – Choice for Health” initiative and refers also to procurement intermediaries. The approach ABHI has taken is founded on carefully commissioned legal advice that was targeted to clarify and challenge the policy intentions of publicly funded bodies. We expect to continue with this approach where it is justified. We will also continue to build relationships with interested parties in the NHS with the aim of making joint progress on procurement. For example, under the leadership of its new President, Lord Hunt of Kings Heath, ABHI has begun discussions with the Health Care Supply Association to establish areas of good practice that could provide benchmarks for both suppliers and buyers.

2011 also saw publication of a National Audit Office report on the procurement of consumables by NHS acute and foundation trusts, followed by a House of Commons Public Accounts Committee (PAC) enquiry. The Department of Health response to this focused on the need for the NHS to have a more effective approach to procurement including better use of information to enable effective benchmarking of products and prices, and leveraging of commitment at scale. A further procurement strategy is due for publication in 2012. ABHI is making strong representation for any strategy to involve industry as a key part of its development, as signalled in the Government’s response to the PAC in summer 2011.

Nishan SuntharesDirector, Commercial and Market Access

Judith MellisSenior Manager, UK Market Affairs

Andy TaylorExecutive Director, Healthcare Policy


ResectoscopeKarl Storz

NHS Chief Executive Innovation ReviewAlongside the Budget statement in March 2011 the Government published ‘The Plan for Growth’ in which the NHS Chief Executive undertook to provide “a report by November 2011, in consultation with industry, academia and other interested parties, on how the adoption and diffusion of innovations can be accelerated across the NHS”. The report was intended to inform the strategic approach to innovation in the reformed NHS and, in calling for evidence, innovation was recognised as essential to the future of the NHS for three important reasons:

Sir Ian Carruthers, Chief Executive for the NHS in Southern England, sought evidence from ABHI and met members of ABHI’s Board in September 2011. The final report, published in December 2011, looks unlikely to take its place on the pile of easily forgotten reports, principally because it provides some clear actions to help with the creation of the NHS Commissioning Board. This is one of the key organisations coming into being once the Health & Social Care Bill completes its passage through Parliament. ABHI expects to involve members in the workstreams to deliver the report: these are expected to address a range of issues important to members, including uptake, investment, procurement and leadership.

1) Innovation improves and extends lives. Innovation in the NHS is about making a real and tangible difference to the lives of millions. Across the NHS, countless patients bear witness to the power of great ideas.

2) Innovation connects and drives quality and productivity in the NHS. The NHS faces a challenging future with increasing financial pressures and continually increasing demand for improved quality of services. It is clear that the NHS must raise its game to develop more high-quality and cost-effective interventions if it is to keep improving.

3) Innovation will support the UK economy. The NHS remains a major investor and wealth creator in the UK, and in science and engineering in particular. Innovation is not just about the future of the NHS and health and social care, it is about the future of our country’s economy too.


International

Strategic VisionMore recently the crisis in the Eurozone has firmly highlighted the importance for our industry to position itself more strategically and look further afield to what many would consider more challenging emerging markets. In our discussions with members throughout 2011 it is apparent that many share this view and have ambitions to build their business interests in Brazil, Russia, India and China (the BRIC economies) more actively than ever before.

In response to our members increasing international focus, during the year ABHI has set out a new strategy for international activity to ensure that it is properly aligned to members’ needs. Following a review of services and support, ABHI has focused and aligning its international priorities to work in three key areas.

1) International Policy Tackle barriers to trade and to identify and capitalise on overseas

opportunities.

2) Trade Promotion To provide a platform for industry to meet customers and policy

makers in key overseas markets.

3) Intelligence & Opportunities To provide valuable market information and highlight potential

opportunities to members.

International Policy GroupThe International Policy Group (IPG) was reformed in 2011: this group set out ABHI’s key markets prioritising a number of the emerging markets and the Middle East region as territories with significant potential for the UK both now and for the future. Work began on identifying and communicating industry concerns over barriers to trade with UK Ministers in both China and Brazil. This will continue to develop over the next 12 months through the IPG and the establishment of several new country working groups.

ABHI’s International Department has been of significant assistance in providing useful insight and information to help in the development of our overseas strategies. ABHI has provided numerous opportunities for us to meet customers and support us in markets around the World. The Policy work that is now underway has opened up a forum to communicate trade issues to the Government and we look forward to continued involvement with ABHI in the future.’

Hans SolerodSmiths Medical

Liz CarringtonManager, Events

Sarah IzonCo-ordinator, Exhibition and Events

Paul BentonDirector, Commercial and International

NeuromateRenishaw


Trade White PaperEarly in 2011 Government announced the publication of its Trade White Paper. ABHI played an active role in the industry consultation process with BIS to ensure members views were represented. We had further dialogue with the CBI ahead of the publication of its export report and ABHI is continuing to work closely with UK Trade & Investment to assist members engagement with the initiatives emerging following the publication of their new five year strategy plan earlier in the year.

It is vital that we create the right conditions for businesses to explore foreign opportunities and this will only be achieved with industry and Government working in partnership. Our focus is on ensuring that support for exporters is effective and that activity is aligned to our sector strengths and requirements. Looking forward, this will remain an important commitment and ABHI will continue to influence the way support is delivered by Government to its members through strong engagement with its stakeholders.

Direct SupportABHI continues to organise the UK participation at a number of key trade shows around the world. Building on the success of our activity in this area, 2011 saw record numbers of companies join our UK groups at Medica in Dusseldorf, Arab Health in Dubai and CMEF in China. ABHI provided enhanced services and profile at these events to ensure that our industry and members continue to be positively promoted overseas and have the opportunity to meet customers and influence policy makers.

Throughout the year ABHI organised a series of international market seminars providing members with the opportunity to learn about markets and gain valuable advice about setting up and growing business overseas. ABHI held its International Conference covering aspects of the Bribery Act, Market Analysis and Barriers to Trade with speakers which included UK Ministers and key policy makers.

2012 will again be a challenging year; however ABHI has now set out a clear strategy and plan to support members and to ensure that our sector grows business overseas.

“Innovation has a vital role to play in fulfilling this purpose by improving the quality of care for patients, releasing savings through productivity, and enabling the NHS to make its contribution as a major investor and wealth creator in the UK.”

Innovation, Health and Wealth Report 2011

StarBurst Talon Radiofrequency AblationAngioDynamics UK


“Historically, the MHRA and ABHI have had an excellent working relationship based on openness, trust and mutual respect. This has worked to the benefit of both, particularly in the regulatory area, in terms of sharing information and ideas. As work on the revision of the devices regulatory regime gathers pace, it is clearly essential that this continues to ensure that the result is a sensible balance between minimum regulation and the need to protect public health and safety.”

Steve Owen MHRA

Regulation

ABHI was established in 1989 in response to the call for a pan European system for device regulation. Some twenty years later the Medical Device Directives are undergoing a major revision (the Revision) and this is producing new challenges which have an increasing relevance and immediacy for UK industry. During 2011 our key priority has been to influence the Revision, working with Eucomed, and at the same time ensuring that the MHRA position is closely aligned to that of industry. Significant agreement was reached between industry and the authorities on designation and control of Notified Bodies, Post Market Surveillance and other key issues. An EU Council Conclusion in June 2011 confirmed that the medical technology industry is regarded as a key innovator providing value for patients across the EU. More importantly, it confirmed that the sector required a regulatory system that would continue to support the timely introduction of innovative medical technology while protecting patient safety.

Advocacy ProgrammeThe medical device industry was rocked by the storm which broke in the spring of 2011 with TV coverage of failed implants and reports of poor quality surgical instruments. These isolated instances of product failure engendered criticism of the regulatory framework by a minority in the clinical community, creating new challenges for ABHI. To meet this criticism head on, we launched an advocacy campaign aimed at dispelling the widespread ignorance of the system among both users and the media. The need for this advocacy work was confirmed by the PIP scandal in December 2011. In this case, the cause of the problem is almost certainly criminal behaviour which no regulatory system can prevent. We continue to argue that the system is a good one and that Revision will effectively address any shortcomings. This work will continue into 2013 and most likely beyond, as the political passage of the Revision will take some years.

Clive PowellManager, Technical and Regulatory

Mike KreuzerExecutive Director, Technical and Regulatory


MHRA Devices DivisionABHI welcomes the creation of a Devices Division in MHRA, having advocated such a move since the merger of MDA and MCA seven years ago. We will work to maintain and increase contacts with the new division during 2013. This will include regular attendance at the meetings of the Committee on the Safety of Devices as observers.

Unique Device IdentificationUnique Identification (UDI) is an issue of immense importance tothe medical technology industry, as the Revision will require devicesto carry a unique identifier. ABHI remains closely involved in thiswork at European level through the Eucomed E-Business and SupplyChain Task Force (ETF) which represents the industry position to theEU Commission and provides representation on the IMDRF (GHTF)UDI Work Team which will oversee the introduction of global standards for UDI.

Standardisation LegislationA review of the EU Standardisation legislation is currently in progress and the importance of standardisation as a vehicle for improved EU competitiveness and productivity has been reaffirmed by the

EU institutions. However poor participation in the standardisation process by national authorities, SMEs and NGOs means that the revised legislation is expected to have new processes to facilitate increased participation by these groups. The connection between the Essential Requirements of the Medical Device Directives and standards was questioned in 2011 by the EU Commission and Sweden raising a ‘formal objection’ to a number of standards. It is expected that the Commission will take a more active interest in the relationship between the Directives and Standards in the future and lively debate is expected in the coming months and years.

Work continues to monitor and report developments in environment legislation particularly REACH and WEEE.

Malcolm CarlisleThis report would not be complete without recording the untimely death of Malcolm Carlisle OBE in late November 2011. Malcolm had contributed more than any other individual to the development of the current regulatory system and as chair of our Technical Policy Group he was looking forward to providing a robust defence of the system in 2012. Malcolm will be greatly missed in this role but more importantly as a friend and colleague to many in ABHI.

Blunt NeedlesBD


The Bribery ActAs might be expected, our principal activities in 2011 concerned the ABHI Code of Business Practice; however we also held a number of events that covered the recently introduced UK Bribery Act and its implications for the medical technology sector. This was well attended and we received good feedback, particularly on the final Q&A section where a panel of experienced compliance professionals gave their experiences of introducing measures designed to reduce the potential for bribery and corruption.

As yet there have been only a few cases brought under the Bribery Act and none so far have involved the medical technology sector. We hope that this will continue to be the case.

Guidelines on Advertising & Promotional MaterialsMuch of our work on ethical and compliance issues takes place in the background and is perhaps not as visible to members as some of ABHI’s other activities. Nonetheless this is a key area of work, requiring a significant amount of resource. The majority of our efforts centre on the ABHI Legal Issues and Compliance Committee whose members are drawn from law firms and companies’ legal and compliance departments. The major achievement of this group in 2011 was the development and launch of the ABHI Guidelines on Advertisements and Promotions addressed solely or primarily to Healthcare Professionals.

Thanks are due particularly to Shuna Mason of CMS Cameron McKenna who began work on the guidelines in 2010. She has successfully developed the paper to the point where it can now be implemented as part of the ABHI Code of Business Practice. A well-attended seminar was held in September 2011 to introduce the guidelines to members and to hear their views. A final version was approved by the ABHI Board in late 2011 to take effect on 1st April 2012.

We believe that these guidelines will be a valuable addition to the Code as we have received frequent enquiries on this subject in the past and where the lack of legislation in this area had meant there was clearly a gap.

Ethical Compliance Logo SchemeAnother important feature of 2011 was the introduction of the ABHI Ethical Business Compliance Logo Scheme. This idea is to establish a recognised symbol recognising companies that not only undertake to comply with the ABHI Code but that have also demonstrated a high-level commitment to compliance and have a structured and ongoing staff training programme.

The scheme has been introduced in parallel to a similar initiative by Eucomed and we plan to extend its availability once the year-long pilot phase has been completed in the autumn of 2012. A number of companies have already signed up to the scheme and we look forward to promoting recognition of the symbol out in the marketplace.

Broadening the Code’s ReachPerhaps the most important piece of work that still needs to be done is to promote the ABHI Code to companies outside its direct membership. If we are truly to succeed in this project then the majority of companies in the industry need to signup and ethical compliance needs to be recognised as being a fundamental element of doing business. We already have commitment from the leadership of the ABHI member trade associations SDMA, BAREMA, BDTA and OPTIC(UK). We have also signed a ‘concordat’ with Medilink UK which will allow us to access the many SMEs in the industry. In 2012 we will work on implementing the administrative tools to allow non-members to sign up. This will be a significant step forward in embedding the Code into the fabric of the UK medical technology business sector.

“The signing of the Concordat in 2011 saw ABHI and Medilink UK formalise an already close relationship. By working together both our organisations can ensure that we provide the highest level of support to all our members- from the smallest right through to the largest. Throughout 2012 and into the future ABHI and Medilink UK will continue to side-by-side to provide the medical device industry with a strong and unified voice.”

Tony DavisMedilink UK

Ethics and Compliance


• Commercial• International• Legal Issues & Compliance Committee• Public Affairs• Technical

• Communications• HCAI• PbR• Sterilisation and Microbiology• Supply Chain and eBusiness• Health Technology Assessment

• Advanced Wound Management• Cardiac Rhythm Management• Elimination of Sharps• Neurosciences• Orthopaedic• Procedure Packs• Spine• Surgical Instruments• Vascular

Board of Directors

Operating Committee

Policy Groups

Working Groups

ABHI Groups Structure

Special Interest Sections


ABHI Board of Directors

ABHI Staff on the Board

Johnny Lundgren ChairmanVice President, North West Europe, Becton Dickinson

Shah Fayyaz Vice Chairman Managing Director, Timesco of London Ltd

Tim CouttsUK Group General Manager Boston Scientific Limited

Jackie FieldingRegional Vice PresidentUK & IrelandMedtronic

Harry Keenan General ManagerBaxter Healthcare Ltd

Philip KennedyManaging DirectorEschmann Holdings Limited

Sandra LawrencePublic Affairs & Health Policy ManagerStryker UK Ltd

James UrieSales and Marketing DirectorMediplus Ltd

Peter EllingworthChief Executive

Mike KreuzerExecutive Director, Technical and Regulatory

Andy TaylorExecutive Director, Healthcare Policy


ABHI Staff List

Peter EllingworthChief ExecutiveMike Kreuzer, OBEExecutive Director, Technical and RegulatoryAndy TaylorExecutive Director, Healthcare PolicyPaul BentonDirector, Commercial and InternationalClive PowellManager, Technical and Regulatory Nishan SuntharesDirector, Commercial and Market AccessJudith MellisSenior Manager, UK Market AffairsDaniel JonesDirector, CommunicationsSarah IzonCo-ordinator, Exhibition and EventsLiz CarringtonManager, EventsLinette IronsManager, FacilitiesMarion HarrisReceptionist/Secretary Assistant, Technical and UK MarketAngela JefferyPA to Chief Executive and Membership Development ManagerEsther MannoukasAccounts AdministratorMonica McStravickAdministrator, UK MarketNicole RoeCommunications AssistantIan CranstonAccountant and Company SecretaryAndy VaughanConsultant, Standards

Membership List

3M Health Care Limited

AA Algeo LtdAbbott Medical OpticsAbbott VascularAccentus Medical plcAdvanced Bionics UK LtdAerocrine LtdAerte LtdAIM Consulting LtdAirsonett UK LimitedAlbert Browne LtdAlcon Laboratories (UK) LimitedAlgotec Research and Development LimitedAltomed LtdAltrax Group LtdAmerican Medical Systems UK LtdAmtac Certification ServicesAnetic Aid LtdAngioDynamics UK LtdAnsell (UK) LtdApaTech LtdApos Medical UK LtdApplied Medical Technology LtdArjoHuntleigh UK LtdArjoHuntleigh, Diagnostic Products DivisionArnold & Porter (UK) LLPAspire Sales Force Development LimitedAvental Ltd

BB. Braun Medical LtdBailey Instruments LtdBaker & McKenzie SolicitorsBakers Instrument Brokers LtdBard LtdBaremaBausch & Lomb UK LtdBaxter Healthcare LtdBecton Dickinson UK LtdBedfont Scientific LtdBiocompatibles UK LtdBiomet UK Healthcare LTDBiotronik UK LtdBircham Dyson Bell LLPBird & Bird LLPBM Polyco LtdBolton Surgical LtdBoston Scientific LtdBristowsBritish Dental Trade AssociationBrowne Health Care LtdBSi

CCalea UK LtdCameron Health UKCarl Zeiss LimitedCaterham Surgical Supplies LtdCeramTecCirrus Healthcare ProductsClement Clarke International LtdClinimax LtdCMS Cameron McKennaCompliance Hub Limited


Conceptus Medical LtdConvaTec LtdCook (UK) LtdCorin LtdCovidien (UK) Commercial LtdCyberonics Europe S.A.

DDDC Dolphin LtdDeltex MedicalDePuy InternationalDePuy UKDixons Surgical Instruments LtdDLA Piper UK LLPDonawa Lifescience ConsultingDTR Medical LtdDurbin plc

EEdwards Lifesciences LtdEschmann EquipmentEuromedica LtdEUSA Pharma (Europe) Ltdev3 LtdEvexar Medical LtdExcellentcare Medical LtdExmoor InnovationsExmoor Plastics Ltd

FFannin UK Ltd, Surgical DivisionFasken Martineau LLPFertility Focus LtdField Fisher Waterhouse LLPFresenius Kabi LtdFull Support Healthcare Ltd

GGalbraithWight LtdGalil Medical UK LtdGAMA Healthcare LtdGlobus Medical UK LtdGriffiths & Nielsen Medical DivisionGS1 UKGSK Consumer HealthcareGuerbet Laboratories Ltd

HH W Andersen Products LtdHaag Streit UK LtdhanoverHarvey Medic LLPHealth Edge Consumables LtdHealth Technology Solutions Spain s.l.Healthlogistics.co.uk LtdHeraeus MedicalHologic UK LtdHorton Ruston PooleHospira UK LtdHull Associates

IIntegra NeuroSciences LtdIvor Shaw Ltd

JJMH Publishing LtdJohn Weiss & Son LtdJohnson & Johnson Medical LtdJRI Orthopaedics LtdJuzo UK Ltd

KK2 Medical Systems LtdK2M UK LtdKapitex Healthcare LtdKarl Storz Endoscopy (UK) LtdKimal PlcKLS Martin UK Ltd

LLabCold LtdLiDCO LtdLifecare Hospital Supplies LtdLifescan UK - a Johnson & Johnson CompanyLloyds Register Quality Assurance LtdLombard Medical Technologies Plc, Cardiovascular DivisionLyall Willis & Co Ltd

MMalaysian Rubber Export Promotion CouncilManagement Forum LtdMathys Orthopaedics LtdMatOrtho LtdMatrix Marking LtdMax Medical Products LtdMDM Medical LtdMecobo LtdMedacta UK LimitedMedartis LtdMedeuronet UK LtdMedi UK LtdMedical Wire & Equipment Co (Bath) LimitedMedicare Colgate LtdMedicom Group LtdMediplus LtdMeditec International England LtdMeditech Systems LtdMedtronic LimitedMedvance LtdMercuri Urval LimitedMi3 LtdMirage Health Group LtdMolnlycke Health Care LtdMoor Instruments LtdMorgan LewisMovianto UK Ltd

Membership List continued


NNew Co-Ordinates LtdNorgine Pharmaceuticals LtdNuVasive UK Ltd

OOlympus KeymedO’Mara Medical SuppliesOPTIC (UK)Ortho Solutions LtdOrthofix LimitedOrthovita UK LtdOwen Mumford Ltd

PP3 Medical LtdPall MedicalPan Globus LtdParburch Medical Developments LtdPDI EuropePentax (UK) LtdPera Innovation LtdPfizer Consumer Healthcare LtdPhagenesis LimitedProcter & Gamble Technical Centres LtdProplink Medical (Europe) LtdPuricore Sterilox EndoscopyPWB Health UK Ltd

QQSpine LtdQuanta Fluid Solutions LtdQuintiles ConsultingQuotec Ltd

RRayner Intraocular Lenses LtdReam Surgical LtdRenfrew Group International LtdRenishaw Diagnostics LtdRenishaw PlcRichard Wolf UK LtdRoberts Surgical Healthcare LtdRSA Group

SS Murray & Co LtdSaharan Trading Company LtdSarstedt LimitedScanTrack Healthcare LtdSchulke and Mayr UK LtdScient’x (UK) LtdScotmed LtdSDMASGS United Kingdom LtdSimmons & Simmons LLPSmart Use LtdSmith & NephewSmithKline Beecham LtdSmiths Medical International LtdSMS Technologies LtdSNR Denton UK LLPSorin Group (UK) LtdSouth Western Surgical Ltd

Sovereign Medical LtdSphinx Medical LtdSpineVision LtdSquire Sanders (UK) LLPSt Jude MedicalStanmore Implants Worldwide LtdStar Syringe LtdSterigenics UK LtdSterilin LtdSTERIS LtdSTOK UK LtdStryker UK LtdSurgi C LtdSurgical HoldingsSurgical Instrument Group Holdings LtdSurgins Surgical LtdSwann-Morton LtdSymmetry MedicalSymmetry Medical Cheltenham LtdSynergus ABSynthes LtdSystagenix Wound Management International Ltd

TTaylor WessingTerumo UK LtdThe Tinnitus Clinic LtdTimesco of LondonTissue Regenix LtdTissue Science Laboratories LtdTomorrow Options - Microelectronics LtdTornier UK LtdTÜV SÜD Product Service Ltd

UUK MAM LtdUK Medical LtdUnderwriters Laboratories LtdUnirose Medical Ltd

VVerathon MedicalVerna Group Ltd

WW L Gore & Associates (UK) LtdWalker MorrisWelch Allyn (UK) LtdWright Medical UK Ltd

XXiros Ltd

ZZimmer Ltd

FSC LOGO TO GO HERE

Association of British Healthcare Industries111 Westminster Bridge RoadLondon SE1 7HRT (020) 7960 4360F (020) 7960 [email protected]

www.abhi.org.uk

ABHI Annual Report 2011

Documents

Transcript of ABHI Annual Report 2011